Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Top Cited Papers
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 158 (5), 1334-1345.e5
- https://doi.org/10.1053/j.gastro.2019.11.296
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2019
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender VariancesThe American Journal of Gastroenterology, 2018
- Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United StatesJournal of Hepatology, 2018
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesJournal of Hepatology, 2017
- Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated CirrhosisGastroenterology, 2007
- Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear importGlycobiology, 2006
- Expression of galectin-3 modulates T-cell growth and apoptosis.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9Biochemistry, 1994
- An endogenous lectin, galectin-3 (ϵBP / Mac-2), potentiates IL-1 production by human monocytesImmunology Letters, 1994
- Galectins: A family of animal β-galactoside-binding lectinsCell, 1994